“Antithrombotic Agents in the Medical Management of Patients with Valvular Disease”
Event Navigation
HealthTrust presents…“Antithrombotic Agents in the Medical Management of Patients with Valvular Disease”
Please Note: Continuing education credit is only available to those attending the session live. CE credit is not available when accessing the program on demand.
The choice of antithrombotic agent after valve replacement has grown increasingly more complex as new data emerges and additional studies produce varying results. Guidelines regarding antithrombotic strategies in patients with valve replacement are continuously updating, with more caveats as to whether certain antithrombotic agents are preferred in specific patient populations. The topic of which antithrombotic agent is most appropriate for the patient is a holistic approach, with considerations of the patient’s potential for bleeding events and their risk factors for cardioembolic events. This session will focus on the use of antithrombotic agents for the medical management of patients with valvular disease who have received a valve replacement with guidelines to assess the risks and benefits of available therapies to determine a patient-specific regimen with a guideline-recommended international normalised ratio (INR) goal for monitoring purposes.
Learning Objectives for Pharmacists & Nurses | At the end of this session, participants should be able to:
- Recall current guideline recommendations on the use of antithrombotic agents in the medical management of patients with valve replacement procedures
- Identify thrombotic risk based on valve position and type of valve utilized in patients with valve replacement procedures
- Recognize the optimal antithrombotic agent and duration of therapy for patients postvalve replacement to balance incidences of thromboembolic and bleeding events
Learning Objectives for Pharmacy Techs | At the end of this session, participants should be able to:
- Recall current guideline recommendations on the use of antithrombotic agents in the medical management of patients with valve replacement procedures
- Identify potential drug and food interactions with antithrombotic agents
- Recognize common antithrombotic agents and duration of therapy for patients postvalve replacement
Presenter:
Mallory McClung, PharmD | PGY1 Pharmacy Resident | Princeton Baptist Medical Center | Birmingham, AL
Target Audience: Pharmacists, Pharmacy Techs & Nurses
CE Credit: Approved for Pharmacists, Pharmacy Techs & Nurses
This program is approved for CPEs by the Accreditation Council for Pharmacy Education (ACPE). Attendees of this program may earn 1.0 CPE Contact Hours. Belmont University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The Universal Activity Numbers for this activity are 0863-9999-24-014-L01-P and 0863-9999-24-014-L01-T. The activity is approved for 1 hour (.1 CEUs) of continuing education credit for Pharmacists, Pharmacy Techs & Nurses who attend the webinar and complete the online evaluation. Pfiedler Education is a division of AORN, provider approved by the California Board of Registered Nursing, Provider Number CEP13019, for 1 contact hour. 1.0 contact hours approved for Nurses.
Note about CE credit: If you plan to obtain credit for a live session, stay until the end of the presentation to receive the verification code you will need to obtain the continuing education credit. CE credit is individual. No group credit is available. Each person must register for a webinar and attend the webinar in its entirety in order to receive an email after the event with instructions on how to apply for continuing education credit. Attendees should not share the code or forward the email to others who did not actually attend the program. If they are not able to be verified on our webinar provider reports and registration list they will not receive credit. If you are joining only by phone, you will not be eligible for credit. You must also log in and join the visual portion of the webinar to be part of our CE provider-required reporting.
